Deutivacaftor + Tezacaftor + Vanzacaftor bulk supplier for pharma manufacturers

Deutivacaftor + Tezacaftor + Vanzacaftor 10 mg + 50 mg + 125mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10 mg + 50 mg + 125mg

Reference Brands: Alyftrek (USA)

Deutivacaftor + Tezacaftor + Vanzacaftor is a Orphan Drugs product available as Tablets in strengths 10 mg + 50 mg + 125mg. It corresponds to the reference brand Alyftrek (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Deutivacaftor + Tezacaftor + Vanzacaftor? List it or send an offer →

Product Description:

This is a next-generation CFTR modulator triple combination for cystic fibrosis. Two corrector molecules help the misfolded CFTR protein traffic correctly to the cell surface, and a potentiator increases the open probability of the channel once it arrives. Deutivacaftor is a deuterated potentiator — replacing hydrogen with deuterium at sites of metabolic attack slows breakdown enough to support once-daily rather than twice-daily dosing.

It is indicated in patients carrying at least one responsive CFTR mutation, with eligibility set by genotype. The clinical case against the established triple therapy rests on once-daily administration and a lower sweat chloride, rather than a large difference in lung function.

Sourcing notes. Originator, on patent, with no generic or biosimilar route. Genotype-gated, so the destination market needs CF genetic testing for the product to be usable at all. Paediatric and adult presentations carry different strengths — confirm which is required, and against the approved presentation rather than a catalogue entry, before quoting.

How Deutivacaftor + Tezacaftor + Vanzacaftor is supplied today, and licensing ahead of patent expiry

Deutivacaftor + Tezacaftor + Vanzacaftor is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Deutivacaftor + Tezacaftor + Vanzacaftor, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Deutivacaftor + Tezacaftor + Vanzacaftor supply →

Back to Listing

Frequently Asked Questions

Alyftrek is used for the treatment of cystic fibrosis in patients aged 6 years and older who have at least one responsive CFTR gene mutation, including the F508del mutation. It helps improve lung function, reduce pulmonary exacerbations, and manage symptoms associated with cystic fibrosis.

Alyftrek contains a combination of three CFTR modulator components: deutivacaftor, tezacaftor, and vanzacaftor. These work together to increase the quantity and function of the CFTR protein at the cell surface.

The trade name of this combination therapy is Alyftrek.

Alyftrek is manufactured and marketed by Vertex Pharmaceuticals Incorporated.

The generic names are deutivacaftor, tezacaftor, and vanzacaftor.

The brand name is Alyftrek.

Alyftrek is manufactured in FDA-, EMA-, and MHRA-approved facilities by Vertex Pharmaceuticals for distribution in the USA, EU, and UK.

Alyftrek (Vanzacaftor + Tezacaftor + Deutivacaftor) is developed and sold by Vertex Pharmaceuticals. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.